The subcutaneous immunoglobulin are the biologic molecules that are injected subcutaneously for the cure of certain diseases/disorders such as infectious diseases, immune deficiencies, and bleeding disorders among others. Due to patient compliance the preference of subcutaneous immunoglobulin is rising over the intravenous route of administration. The global subcutaneous immunoglobulin market expected to witness a lucrative growth during the forecast period owing to the growing burden of primary immunodeficiency diseases, rising geriatric population and opportunities for immunoglobulins for secondary immunodeficiency diseases treatment.

The global subcutaneous immunoglobulin market is segmented based on the application, end-users, and geography. Based on the application, the global subcutaneous immunoglobulin market is segmented into secondary immunodeficiency diseases, primary immunodeficiency diseases, and others diseases. Others segment include neurological disorders, infectious diseases, bleeding disorders etc.

In 2024, the primary immunodeficiency diseases segment dominated the global market owing to the growing prevalence such diseases and surging research and developments. Based on the end-users, the global market is segmented into home care, hospitals, and clinics.

In 2024, the hospitals segment led the market and homecare segmented is identified as the fastest growing segment. The preference of the patient and ease of use for the subcutaneous immunoglobulin administration accounted for the rapid growth of the homecare segments.

In 2024, the North America accounted for the major share in global subcutaneous immunoglobulin market owing to the rise in geriatric population, technological advancements and initial launch of products. According to the U.S. Census Bureau, the population equal to and above 60 years of age in United States will rise to 12.67% in 2026 from 10.90%, which indicates the high demand of subcutaneous immunoglobulin during the forecast period. According to the Immune Deficiency Foundation, in 2015, an approximate of 55,000 patients in the United States were treated with primary immunodeficiency diseases and the cases are expected to grow during the forecast period.

The manufacturers are competing heavily in the market based on the pricing and the approaches to effectively deliver the immunoglobulin in the patient’ body. For instance, Shire Plc has developed a product, Hyquia, which consist of dual vial unit, one for immunoglobulin infusion 10% and another for recombinant human hyaluronidase. The simultaneous subcutaneous administration of both the formulations enhances the bioavailability of the immunoglobulin and allows infusion of large volume.

Key Developments:

• In March 2019, Takeda Pharmaceutical Company Limited received U.S. FDA approval to manufacture flexbumin at new plasma manufacturing facility near Covington, Georgia
• In July 2019, Grifols S.A. received the USFDA approval for Xembify for treatment of primary immunodeficiencies.
• In September 2018, CSL Behring received the Australian Therapeutic Goods Administration (TGA) approval for Hizentra for treatment of CIDP

Key Players Identified in Subcutaneous Immunoglobulin (SCIg) Market include:

Baxalta Incorporated, Biotest AG, CSL Behring, LLC, Grifols S.A., Kedrion S.p.A., Octapharma AG, Shire Plc, Talecris Biotherapeutics, Inc. And Others.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Subcutaneous Immunoglobulin (SCIg) market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Subcutaneous Immunoglobulin (SCIg) market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Subcutaneous Immunoglobulin (SCIg) market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Subcutaneous Immunoglobulin (SCIg) market?
• Which is the largest regional market for Subcutaneous Immunoglobulin (SCIg) market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Subcutaneous Immunoglobulin (SCIg) market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Subcutaneous Immunoglobulin (SCIg) market worldwide?